Abstract
Currently, the pharmaceutical heparin being used as an anticoagulant is isolated from bovine lungs or porcine intestines. The primary problem resulting from heparin isolation from animal sources is that this process leaves the heparin open to contamination from animal pathogens that may also be infectious to humans. Enzymatic production of heparin anticoagulant is an attractive alternative to animal derived heparin as it removes the potential for contamination with animal pathogens and also potentially reduces molecular heterogeneity. Heparosan, produced in bacteria, has a structure similar to the backbone structure of heparin and therefore is used as a precursor in the enzymatic production of heparin anticoagulant using various recombinant sulfotransferases. After production, the synthetic heparin was assessed for anticoagulant activity. This approach offers a great promise for human use in the coming years.Supported by NIHLBI grant HL107152.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
